Clinical efficacy and safety of sodium glucose cotransporter 2 inhibitors - experience in a regional hospital

  • At: 2017 FIP Congress in Seoul (South Korea)
  • Type: Poster
  • By: TSENG, Hsiang-Yi (Tungs’ Taichung MetroHarbor Hospital, Department of Pharmacy, Taichung, China Taiwan)
  • Co-author(s): Hsiang-Yi Tseng: Department of Pharmacy, Tungs’ Taichung MetroHarbor Hospital, Taichung, Taiwan, Province of China;, Taichung City New Pharmacist Association, Taichung, Taiwan, Province of China
    Wen-Cheng Hsu: Department of Endocrinology and Metabolism, Tungs’ Taichung MetroHarbor Hospital, Taichung, Taiwan, Province of China
    Hui-Chun Tsai: Diabetes Mellitus Education Room, Tungs’ Taichung MetroHarbor Hospital, Taichung, Taiwan, Province of China
    Pei-Liang Chen: Department of Pharmacy, Tungs’ Taichung MetroHarbor Hospital, Taichung, Taiwan, Province of China;, Taichung City New Pharmacist Association, Taichung, Taiwan, Province of China
  • Abstract:

    Methods

    It is a preliminary, retrospective cohort study. T2DM patients added or shifted SGLT2i to their existing therapy from June 2016 to January 2017 in a single hospital in Taiwan were identified. Cases with complete before-and-after HbA1c, eGFR (according to the Modification of Diet in Renal Disease formula), random urine protein: creatinine..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login